• Explore /
  • Poster
  • / A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.

Abstract Poster

Authors

null

Nehal J. Lakhani

START-Midwest, Grand Rapids, MI

Nehal J. Lakhani, Amita Patnaik, John B. Liao, John William Moroney, David S. Miller, Gini F. Fleming, Matt Axt, Yan V. Wang, Balaji Agoram, Jens-Peter Volkmer, Roy Maute, Andreas Schroeder, Isagani Chico, Mark Chao, Chris H.M. Takimoto, Kathleen N. Moore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT03558139

Citation

J Clin Oncol 38, 2020 (suppl 5; abstr 18)

Abstract #

18

Poster Bd #

B12

Abstract Disclosures

Similar Posters

First Author: Mary L. Disis

First Author: Andrea B. Apolo

First Author: Manish R. Patel

First Author: Monica Khunger